|
R&D Pipeline News Vol. 2, Issue 11: inclu. Anti-CD20 Antibody Pipeline |
|
|
|
21 Mar 2006 |
 |
| |
Special Pipeline
Special Company Pipelines
|
Vol. 2 Issue nº 11
March 20, 2006
|
 |
|
|
|
|
|
Special Pipeline
|
1. Anti-CD20 Antibody Pipeline
|
- Several generations of anti-CD20 murine, chimeric, humanized, human antibodies and derivatives;
- New generations of anti-CD20 preferrably in development for rheumatoid arthritis;
- close competition field of anti-CD20 antibodies in phase II for rheumatoid arthritis;
-
|
|
|
Special Company Pipelines
|
1. Genentech’s Development Pipeline
|
- Massive development program for Avastin line extensions;
- Life cycle management for marketed products dominates clinical pipeline;
- Focus on oncology and immunology
- Mainly biologics in clinical pipeline,
- Four different clinical stage projects in rheumatoid arthritis
|
2. Zealand Pharma (Denmark)
|
- Specialized on peptide drugs;
- Successful in licensing-out,
- New peptide against chemotherapy-induced diarrhea soon to enter phase I
|
3. UCB (Belgium)
|
- Anti-epileptic drug Keppra most successful product with rich line extension program;
- Two follow-up projects for Keppra in phase II;
- Celltech projects fill the pipeline;
- Anti-TNF CIMZIA file submitted in US and soon in Europe
|
|
R&D Pipeline News
Get your Subscription Now
|
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now
 
|
|
|
|
|
|
|
|
| |
|
